The effect of mogamulizumab on the aberrant T cell population in the peripheral blood – A monocentric retrospective analysis
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2023
DOI: 10.1111/ddg.15144 ↗Kurz gefasst
Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2023. Verfasst von Janika Gosmann und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Department for Dermatology, Venereology, Allergology and Phlebology, Skin Cancer Center, Johannes Wesling Medical Center Minden, Ruhr Univ…. Hauptthemen laut MEDLINE: Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background and Objectives The effect of mogamulizumab in cutaneous T‐cell lymphoma (CTCL) on T cells (TC) in the peripheral blood and its potential role to navigate treatment intervals are explored.
Methods
We investigated within a retrospective monocentric analysis the effect of mogamulizumab on the CD3 + TC and the aberrant T cell population (TCP), i.e., the CD4 + /CD7 – and the CD4 + /CD26 – TC, analyzed by flow cytometry.
Results
Thirteen patients with CTCL were included. After four cycles there was a mean reduction of 57% in CD3 + TC, 72% in the CD4 + /CD7 – and 75% in the CD4 + /CD26 – TCP compared to the individual baseline of each patient. The reduction in CD4 + /CD7 + and CD4 + /CD26 + TC was lower, averaging 54% and 41%. A significant decrease in aberrant TCP was already evident after the first administration. A median plateau of TCP already occurred during the IP. Progressive disease occurred in 5/13 patients without a clear correlation to aberrant TCP.
Conclusions
Already after one dose of mogamulizumab, aberrant TCP and, to a lesser extent, normal TC decrease. We did not observe a clear correlation between TCP and the efficacy of mogamulizumab, but further studies with larger numbers of patients are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Department for Dermatology, Venereology, Allergology and Phlebology, Skin Cancer Center, Johannes Wesling Medical Center Minden, Ruhr University Bochum, Minden, Germany.
- Institute for laboratory medicine, microbiology, environmental medicine and transfusion medicine, Johannes Wesling Medical Center Minden, Ruhr University Bochum, Minden, Germany.
- Department of Dermatology, Allergology and Venereology, Hannover Skin Cancer Center (HTZH), Hannover Medical School, Hannover, Germany.
Zitieren
APA
Gosmann, J., Bielefeld, A., Schmitz, F. J., Schaper-Gerhardt, K., Gutzmer, R., & Stadler, R. (2023). The effect of mogamulizumab on the aberrant T cell population in the peripheral blood – A monocentric retrospective analysis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15144
Vancouver
Gosmann J, Bielefeld A, Schmitz FJ, Schaper-Gerhardt K, Gutzmer R, Stadler R. The effect of mogamulizumab on the aberrant T cell population in the peripheral blood – A monocentric retrospective analysis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2023. doi:10.1111/ddg.15144
BibTeX
@article{Gosmann2023,
author = {Gosmann, Janika and Bielefeld, Annette and Schmitz, Franz-Josef and Schaper-Gerhardt, Katrin and Gutzmer, Ralf and Stadler, Rudolf},
title = {The effect of mogamulizumab on the aberrant T cell population in the peripheral blood – A monocentric retrospective analysis},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2023},
doi = {10.1111/ddg.15144}
}
EUVIMED